18 results
The primary objective is to evaluate the difference in 68Ga-exendin tracer accumulation in the pancreas of patients with and without complete resolution of T2DM after RYGB by quantitative analysis of PET images.
The main objective is to examine if 68Ga-exendin tracer accumulation (i.e. beta cell mass) differs in patients with persisting HH after RYGB compared to matched patients without HH after RYGB. The secondary objectives are:- compare GLP1 and GIP…
This study aims at (further) revealing the pathophysiology of intestinal IR in man, with a specific interest for the role of proteases and protease-activated receptor-2 (PAR-2), cellular and inflammatory changes, barrier function and intestinal…
Studies examining the effect of couple therapy or couple-based interventions in treatment for personality disorder are very scarce and more research is required. Therefore, the present study examines the effect of couple-based interventions in…
This study had two objectives:1. which factors determine outcome of treatment of children with functional childhood constipation referred to the outpatient clinic of multidisciplinary treatment clinics in the Netherlands;2. which factors can be…
The main objective is to examine the change in 68Ga-exendin tracer accumulation in the pancreas (i.e. beta cell mass) after RYGB by quantitative analysis of PET images before and one year after RYGB in morbid obese patients with type 2 diabetes.
Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…
To evaluate the long-term safety and efficacy of RPC1063 for the treatment of all patients with moderate to severe UCTo evaluate the long-term efficacy of RPC1063 for the treatment of adult patients with moderate to severe UC.
This study has been transitioned to CTIS with ID 2023-505699-31-00 check the CTIS register for the current data. To evaluate the Long-Term Safety and Efficacy of upadacitinib.
The aim of this project is to identify biomarkers and novel therapeutic targets for pediatric Hodgkin lymphoma. To achieve this aim we defined three objectives:1.Hodgkin Reed-Sternberg cells: To perform whole exome sequencing and gene expression…
To increase the major pathological response rate (< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer.
The main goal of this study is to explore the pattern of physiologic and pathophysiologic cardiac recovery after a preeclamptic pregnancy compared to a normotensive pregnancy, up till 18 months PP.To study the link between placental acute atherosis…
to compare the efficacy and safety of complex fractionated atrial electrocardiograms (CFAEs) guided ablation to pulmonary vein isolation based ablation in patients with persistent atrial fibrillation (AF).
The primary objective of the study is:- to evaluate the burden of AF and quality of life rhythm after thoracoscopic ablation surgery and after port-access concomitant left atrial MAZE surgery by continuous rhythm monitoring (Medtronic Reveal Linq…
Improve allo-SCT transplant outcome using a uniform conditioning regimen and pacritinib pretreatment by means of the proportion of patients with a failure within 6 months post-transplant. Events that are considered a failure are: primary graft…
This study has been transitioned to CTIS with ID 2025-520487-18-00 check the CTIS register for the current data. To determine the activity of nivolumab after four different immune response induction treatments in TNBC patients with metastatic…
This study has been transitioned to CTIS with ID 2024-517410-15-01 check the CTIS register for the current data. The aim of this study is to determine the oncological safety, treatment related morbidity, and the functional outcome of local excision…
Primary objectives: To explore the safety, feasibility, and the immune-activating capacity of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapySecondary…